These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 30605918)

  • 1. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
    Paciullo F; Momi S; Gresele P
    Thromb Haemost; 2019 Mar; 119(3):359-367. PubMed ID: 30605918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V
    Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract]   [Full Text] [Related]  

  • 3. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
    Chamberlain AM; Gong Y; Shaw KM; Bian J; Song WL; Linton MF; Fonseca V; Price-Haywood E; Guhl E; King JB; Shah RU; Puro J; Shenkman E; Pawloski PA; Margolis KL; Hernandez AF; Cooper-DeHoff RM
    J Am Heart Assoc; 2019 May; 8(9):e011246. PubMed ID: 31020929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PCSK9 revolution: Current status, controversies, and future directions.
    Warden BA; Fazio S; Shapiro MD
    Trends Cardiovasc Med; 2020 Apr; 30(3):179-185. PubMed ID: 31151804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
    Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M
    Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 inhibition 2018: riding a new wave of coronary prevention.
    Ward NC; Page MM; Watts GF
    Clin Sci (Lond); 2019 Jan; 133(2):205-224. PubMed ID: 30670671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up.
    Barale C; Bonomo K; Frascaroli C; Morotti A; Guerrasio A; Cavalot F; Russo I
    Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):282-291. PubMed ID: 31653513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
    Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Nabavi SM; Lavie CJ; Banach M;
    Prog Cardiovasc Dis; 2021; 67():65-74. PubMed ID: 33383060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid management in ACS: Should we go lower faster?
    Gencer B; Mach F
    Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?
    Noto D; Giammanco A; Barbagallo CM; Cefalù AB; Averna MR
    Cardiovasc Res; 2018 Oct; 114(12):1595-1604. PubMed ID: 29931148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors.
    Alali RA
    Rev Cardiovasc Med; 2019 Mar; 20(1):1-8. PubMed ID: 31184090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 inhibitors: clinical evidence and implementation.
    Sabatine MS
    Nat Rev Cardiol; 2019 Mar; 16(3):155-165. PubMed ID: 30420622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 20. What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
    Alakbarzade V; Pereira AC
    J Stroke Cerebrovasc Dis; 2020 Jan; 29(1):104457. PubMed ID: 31732461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.